Carbidopa

Aromatic Amino Acid Decarboxylation Inhibitor

Key facts

Carbidopa is an ofp drug in the Aromatic Amino Acid Decarboxylation Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 1975. Its mechanism of action is classified as DOPA Decarboxylase Inhibitors. DrugCentral lists 4 molecular targets, including KDM4E, FYN and LCK. Recorded indications include Parkinson's disease, Parkinsonism and Postencephalitic parkinsonism.

• Approval status: ofp (first approved 1975 by the FDA).
• Drug class: Aromatic Amino Acid Decarboxylation Inhibitor.
• Mechanism of action: DOPA Decarboxylase Inhibitors.
• Molecular targets: KDM4E, FYN, LCK and DDC (4 listed in DrugCentral).
• Indications: Parkinson's disease, Parkinsonism and Postencephalitic parkinsonism.
• Molecular formula: C10H14N2O4; molecular weight 226.23 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

• Parkinson's disease
• Parkinsonism
• Postencephalitic parkinsonism

Off-label uses (1)

• Restless legs

Contraindications (31)

• Acute disease of cardiovascular system
• Acute nephropathy
• Angle-closure glaucoma
• Cardiovascular event risk
• Cataract surgery
• Conduction disorder of the heart
• Depressive disorder
• Diabetes mellitus
• Diarrhea
• Disease of liver
• Disorder of lung
• Drug-induced psychosis
• Duodenal ulcer disease
• Dyskinesia
• Gastric ulcer
• Gastrointestinal hemorrhage
• Hallucinations
• Hepatic failure
• Intraoperative floppy iris syndrome
• Kidney disease
• Malignant melanoma
• Myocardial infarction
• Obstruction of bile duct
• Open-angle glaucoma
• Orthostatic hypotension
• Peptic ulcer
• Psychoneurotic personality disorder
• Psychotic disorder
• Retention of urine
• Seizure disorder
• + 1 more

Mechanism & targets

• Mechanism of action (MoA): DOPA Decarboxylase Inhibitors
• Established pharmacologic class: Aromatic Amino Acid Decarboxylation Inhibitor

Molecular targets (4)

Target	Gene	Action	Activity
Lysine-specific demethylase 4E	KDM4E	unknown	Ki 5.70
Tyrosine-protein kinase Fyn	FYN	unknown	IC50 5.43
Tyrosine-protein kinase Lck	LCK	unknown	IC50 5.17
Aromatic-L-amino-acid decarboxylase	DDC	inhibitor	—

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2010-10-17	EMA	—	Orion Corporation
1975-05-02	FDA	—	MERCK SHARP DOHME

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Parkinson's disease	457.6
Hallucination	440.3
Dyskinesia	312.6
Gambling disorder	255.6
Hallucination, visual	246.8
Fall	185.8
Muscle rigidity	180.3
Hypersexuality	171.9
Tremor	157.1
On and off phenomenon	125.0
Confusional state	119.7
Neuroleptic malignant syndrome	119.0

Chemical structure

• Molecular formula: C₁₀H₁₄N₂O₄
• Molecular weight: 226.23 g/mol
• CAS number: —
• InChIKey: TZFNLOMSOLWIDK-JTQLQIEISA-N
• PubChem CID: 34359

C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Carbidopa used for?

DrugCentral lists the following indications for Carbidopa: Parkinson's disease, Parkinsonism and Postencephalitic parkinsonism.

How does Carbidopa work?

Carbidopa is classified as DOPA Decarboxylase Inhibitors; its molecular targets in DrugCentral include KDM4E, FYN, LCK and DDC (inhibitor).

When was Carbidopa first approved?

Carbidopa was first approved by the FDA in 1975.

What drug class does Carbidopa belong to?

Carbidopa is in the Aromatic Amino Acid Decarboxylation Inhibitor class.

What is the chemical formula of Carbidopa?

Carbidopa has the molecular formula C10H14N2O4 and a molecular weight of 226.23 g/mol.

Sources

• DrugCentral drug card 496 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1200748 — compound record and bioactivity
• PubChem CID 34359 — chemical identifiers
• DrugBank DB00190 — drug record
• FDA UNII MNX7R8C5VO — substance identity
• DailyMed: FDA labels for Carbidopa — current prescribing information (label search)
• UniProt B2RXH2 (KDM4E) — target protein
• UniProt P06241 (FYN) — target protein
• UniProt P06239 (LCK) — target protein
• UniProt P20711 (DDC) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.